Garofano, Luciano http://orcid.org/0000-0001-8582-0865
Migliozzi, Simona
Oh, Young Taek
D’Angelo, Fulvio http://orcid.org/0000-0002-4940-4693
Najac, Ryan D.
Ko, Aram
Frangaj, Brulinda
Caruso, Francesca Pia http://orcid.org/0000-0002-2206-1459
Yu, Kai
Yuan, Jinzhou
Zhao, Wenting
Di Stefano, Anna Luisa
Bielle, Franck
Jiang, Tao http://orcid.org/0000-0002-7008-6351
Sims, Peter
Suvà, Mario L.
Tang, Fuchou http://orcid.org/0000-0002-8625-7717
Su, Xiao-Dong
Ceccarelli, Michele http://orcid.org/0000-0002-4702-6617
Sanson, Marc
Lasorella, Anna http://orcid.org/0000-0002-1839-5421
Iavarone, Antonio http://orcid.org/0000-0002-0683-4634
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (R01CA101644, U54CA193313, R01CA131126, R01CA178546, U54CA193313, R01CA179044, R01CA190891, R01CA239698)
Associazione Italiana per la Ricerca sul Cancro (IG 2018 ID. 21846)
The Chemotherapy Foundation grant to A.I.
Article History
Received: 10 June 2020
Accepted: 25 November 2020
First Online: 11 January 2021
Competing interests
: A.L. and A.I. are inventors of a biomarker technology that has been licensed to QIAGEN. A.I. received sponsored research funding from AstraZeneca and Taiho Pharmaceutical and has served as a paid consultant/advisor to AIMEDBIO Inc. A.L. received sponsored research funding from Celgene. All other authors declare no competing interests.